JPS5928396B2 - Novel plasmid with tetracycline resistance - Google Patents
Novel plasmid with tetracycline resistanceInfo
- Publication number
- JPS5928396B2 JPS5928396B2 JP57157366A JP15736682A JPS5928396B2 JP S5928396 B2 JPS5928396 B2 JP S5928396B2 JP 57157366 A JP57157366 A JP 57157366A JP 15736682 A JP15736682 A JP 15736682A JP S5928396 B2 JPS5928396 B2 JP S5928396B2
- Authority
- JP
- Japan
- Prior art keywords
- plasmid
- bacillus
- tetracycline resistance
- dna
- tetracycline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000013612 plasmid Substances 0.000 title claims description 35
- 239000004098 Tetracycline Substances 0.000 title claims description 20
- 235000019364 tetracycline Nutrition 0.000 title claims description 20
- 150000003522 tetracyclines Chemical class 0.000 title claims description 20
- 229960002180 tetracycline Drugs 0.000 title claims description 19
- 229930101283 tetracycline Natural products 0.000 title claims description 19
- 108091008146 restriction endonucleases Proteins 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 241000894006 Bacteria Species 0.000 description 21
- 108020004414 DNA Proteins 0.000 description 18
- 108090000790 Enzymes Proteins 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 13
- 229940088598 enzyme Drugs 0.000 description 13
- 241000193830 Bacillus <bacterium> Species 0.000 description 12
- 239000013598 vector Substances 0.000 description 11
- 244000063299 Bacillus subtilis Species 0.000 description 10
- 235000014469 Bacillus subtilis Nutrition 0.000 description 10
- 238000003776 cleavage reaction Methods 0.000 description 8
- 210000001938 protoplast Anatomy 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 102000016943 Muramidase Human genes 0.000 description 4
- 108010014251 Muramidase Proteins 0.000 description 4
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229960000274 lysozyme Drugs 0.000 description 4
- 239000004325 lysozyme Substances 0.000 description 4
- 235000010335 lysozyme Nutrition 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000606790 Haemophilus Species 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 2
- 241000606766 Haemophilus parainfluenzae Species 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- 201000004283 Shwachman-Diamond syndrome Diseases 0.000 description 2
- 241000589596 Thermus Species 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241001468186 Caryophanon latum Species 0.000 description 1
- 108091092566 Extrachromosomal DNA Proteins 0.000 description 1
- 241000606788 Haemophilus haemolyticus Species 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000589499 Thermus thermophilus Species 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000012262 fermentative production Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000002306 tributylsilyl group Chemical group C(CCC)[Si](CCCC)(CCCC)* 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
Landscapes
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
Description
【発明の詳細な説明】
本発明は好熱菌を宿主とする組換えDNA実験のベクタ
ーとして有用が新規なプラスミドに関するものであり、
より詳しくはテトラサイクリン耐性の遺伝子を内部に備
え、その分子量が約2.8メガダルトンであり、図に示
される制限酵素開裂地図によ修特徴づけられる新規なプ
ラスミドに関す□るものである。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a novel plasmid useful as a vector for recombinant DNA experiments using thermophilic bacteria as a host.
More specifically, it relates to a novel plasmid that contains a tetracycline resistance gene, has a molecular weight of approximately 2.8 megadaltons, and is characterized by the restriction enzyme cleavage map shown in the figure.
従来、粗換えDNA実験は主として大腸菌を宿主とする
係で広く研究がおこなわれインシュリン、インターフェ
ロン、ヒト成長ホルモン等が大腸菌で量産されるなど大
きな成果を挙げている。Conventionally, crude DNA experiments have been widely conducted mainly using Escherichia coli as a host, and great results have been achieved, such as the mass production of insulin, interferon, human growth hormone, etc. using Escherichia coli.
大腸菌の宿主−ベクター系ははゾ完成されており、また
大腸菌以外にも酵母、枯草菌などで宿主−ベクター系が
開発され応用への道が検討されつつある。The host-vector system of Escherichia coli has been fully developed, and in addition to Escherichia coli, host-vector systems have been developed in yeast, Bacillus subtilis, etc., and avenues for application are being considered.
しかし、上記の菌はいずれも生育温度が30°C〜37
℃の中温菌である点に問題がある。However, all of the above bacteria have a growth temperature of 30°C to 37°C.
The problem is that it is a mesophilic bacterium with a temperature of ℃.
一方、好熱性細菌は、生育上限湿度が55℃〜75℃に
ある中等度好熱菌と、生育上限湿度が75℃以上である
高度好熱菌とに大別されるが、いずれについても、その
有する酵素、生体成分が耐熱性、耐溶媒性に優れている
事が知られており、とりわけ好熱菌由来の耐熱性酵酵及
び耐熱性生体機能のバイオリアクター等の工業プロセス
への応用という点から注目を集めている。On the other hand, thermophilic bacteria are broadly divided into moderate thermophiles, which have an upper limit of growth humidity between 55°C and 75°C, and extreme thermophiles, which have an upper limit of growth humidity of 75°C or higher. It is known that the enzymes and biological components it contains have excellent heat resistance and solvent resistance, and are particularly useful for industrial processes such as heat-resistant fermentation derived from thermophilic bacteria and bioreactors with heat-resistant biological functions. It is attracting attention from a number of points.
従って、好熱性細菌の育種が重要と考えられるが、その
為の一つの、しかも有力な手段と考えられる好熱性細菌
の宿主−ベクター系の開発研究については、ベクターの
有力候補と考えられるプラスミドの検索を含めても以下
の報告しか知られていない。Therefore, the breeding of thermophilic bacteria is considered to be important, and research on the development of host-vector systems for thermophilic bacteria, which is considered to be one of the most effective means for this purpose, is necessary. Even after searching, only the following reports are known.
(1)高度好熱菌よりの染色体外DNAの分離ヒシヌマ
、F、タナカ、T、アンド サカグチ、K。(1) Isolation of extrachromosomal DNA from highly thermophilic bacteria Hishinuma, F., Tanaka, T., and Sakaguchi, K.
J、Gen、Microt)、 104,193−19
9(1978)
(2)薬剤耐熱の好熱性バチルス属細菌よりの4種類の
プラスミドの分離とその性質の部分解析ピングハム、
A、H,A、、ブルドン、 C,J、アンド アト
キンソン、T。J. Gen. Microt), 104, 193-19.
9 (1978) (2) Isolation of four types of plasmids from drug-resistant thermophilic Bacillus bacteria and partial analysis of their properties Pingham,
A.H.A., Bourdon, C.J., & Atkinson, T.
J、Gen、Microb、 、 114. 401−
408(1979)(3) バルルス°ステアロサー
モフィルスのプラスミドpAB124の解析及び欠失誘
導体の創製ピングハム、A、H,A、 、 ブルドン
、C’、J、アンド アトキンソン、T。J, Gen, Microb, 114. 401-
408 (1979) (3) Analysis of plasmid pAB124 of Barurus stearothermophilus and creation of deletion derivatives Pingham, A, H, A, Bourdon, C', J, and Atkinson, T.
J、Gen1M1crob、、 119.109−11
5(1980)(4)好熱性バチルス属細菌よりの薬剤
耐性プラスミドの分離と解析、及び部分欠失プラスミド
の創製
イマナカ、T、、フジイ2M、アンド アイバ、s。J, Gen1M1crob,, 119.109-11
5 (1980) (4) Isolation and analysis of drug-resistant plasmids from thermophilic Bacillus bacteria and creation of partially deleted plasmids Imanaka, T., Fujii 2M, and Aiba, s.
J、Bact、 146(3)、 1091−109
7 (1981)(5)サーマス・サーモフィルスから
単離されたプ゛ラスミド(pTTI)の物理的性状
上ベルハード、M、D、、バスクエス、C1,ヒレンズ
エラ、P、ビキュナ、R,アンド ユデレビツク、A。J, Bact, 146(3), 1091-109.
7 (1981) (5) Berhard, M.D., Vasquez, C.1., Gilenzuela, P., Vicuna, R., and Yudelevik, on the physical properties of plasmid (pTTI) isolated from Thermus thermophilus. A.
P Iasmid、6. 1−6 (1981)(6)
プラスミドDNAによるバチルス・ステアロサーモフィ
ルスの形質転換及びバチルス・ステアロサーモフィルス
バチルス・ズブチルス間共用ベクターの性質
イマナカ、T、、フジイ2M、、アラモリ、■、アンド
アイバ、S。P Iasmid, 6. 1-6 (1981) (6)
Transformation of Bacillus stearothermophilus with plasmid DNA and properties of Bacillus stearothermophilus shared vectors Imanaka, T., Fujii 2M, Aramori, ■, and Aiba, S.
J、Bact、149(3)、824−830(198
2)そこで、本発明者らは、その宿主が好熱性の微生物
であって、その内部にテトラサイクリン耐性の遺伝子を
備えた微生物を自然界より検索した結果、バチルス属に
属する一菌株から新規なプラスミドを得ることに成功し
た。J, Bact, 149(3), 824-830 (198
2) Therefore, the present inventors searched the natural world for microorganisms whose host is a thermophilic microorganism and which contains a tetracycline resistance gene, and as a result, they discovered a new plasmid from a strain belonging to the genus Bacillus. succeeded in obtaining it.
このプラスミドは前記の制限酵素開裂地図に示され、分
子量は小さく、また種々の制限酵素による特異的な切断
点を有し、テトラサイクリンに対する耐性遺伝子をプラ
スミドDNA上に有している。This plasmid is shown in the above restriction enzyme cleavage map, has a small molecular weight, has specific cleavage points by various restriction enzymes, and has a tetracycline resistance gene on the plasmid DNA.
(以下、本プラスミドをIpTHTt5Jと略称する。(Hereinafter, this plasmid will be abbreviated as IpTHTt5J.
なお、図に示されている制限酵素の略称は次のとおりで
ある。The abbreviations of the restriction enzymes shown in the figure are as follows.
(1) C1alはカリオファノン・ラツム由米の酵
素(2) E coRIはニジエリビア・ユリ由来の
酵素(3)Hhalはハエモフイルス・バエモリティカ
ス由来の酵素
(4)HpaIはハエモフイルス・パラインフルエンザ
由来の酵素
(5)Hpallはハエモフイルス・パラインフルエン
ザ由来由来の酵素
(6)TaqIはサーマス・ア・ノアティカス由来の酵
素を示す。(1) C1al is an enzyme derived from Caryophanon latum yume (2) E coRI is an enzyme derived from Nijieribia lily (3) Hhal is an enzyme derived from Haemophilus baemolyticus (4) HpaI is an enzyme derived from Haemophilus parainfluenza (5) Hpall indicates an enzyme derived from Haemophilus parainfluenza (6) TaqI indicates an enzyme derived from Thermus a noaticus.
以下、テトラサイクリン耐性を有する既知の好熱菌由来
のプラスミドとの相違点を表に示す。Differences from plasmids derived from known thermophilic bacteria having tetracycline resistance are shown in the table below.
表から明らかなように、T)THT15は既知のプラス
ミドに較べ、分量、制限酵素による切断パターンが明ら
かに異なっており、新規なプラスミドであることが認め
られる。As is clear from the table, T)THT15 is clearly different in quantity and restriction enzyme cleavage pattern compared to known plasmids, and is recognized as a novel plasmid.
プラスミドDNAがベクターたり得る為には、そのプラ
スミドが宿主内での自律的増殖能、及び選択マーカー(
そのプラスミドが宿主内に存在していることを示すマー
カー)を有していることが必須であるが、pTHT15
は好熱菌及び枯草菌での自律的増殖能及びテトラサイク
リン耐性という極めて選択に有利なマーカーを有してい
る。In order for plasmid DNA to be used as a vector, the plasmid must have the ability to autonomously reproduce within the host and a selection marker (
It is essential that the plasmid has a marker indicating that it is present in the host, but pTHT15
has extremely advantageous selection markers such as the ability to grow autonomously in thermophilic bacteria and Bacillus subtilis, and resistance to tetracycline.
更にI)THT15は図からも明らかなように、C1a
l、EcoRI、Hpal、Hpallなどの制限酵素
による開裂部位を特定のしかも限られた位置に有してい
る。Furthermore, I) THT15 is C1a, as is clear from the figure.
It has cleavage sites by restriction enzymes such as 1, EcoRI, Hpal, and Hpall at specific and limited positions.
このことはpTHT15をベクターとして利用する際に
、挿入すべき異種遺伝子の導入部位を有意に保持できる
という点で有利である。This is advantageous in that when pTHT15 is used as a vector, a site for introducing a heterologous gene to be inserted can be significantly retained.
また、pTHT15は枯草菌でも好熱菌でもベクターと
して利用できる点で有利である。Further, pTHT15 is advantageous in that it can be used as a vector for both Bacillus subtilis and thermophilic bacteria.
従って、pTHT15をベクターとして用いることによ
り異種遺伝子を同時に枯草菌と好熱菌にクローン化する
ことも可能である。Therefore, by using pTHT15 as a vector, it is also possible to simultaneously clone a heterologous gene into Bacillus subtilis and a thermophilic bacterium.
また、枯草菌とpTHT15の分離源である好熱菌、バ
チルス、ステアロサーモフィルスとはバチルス属に属す
るという共通点を有するためその近縁性から既に枯草菌
で発現している異種遺伝子は、好熱菌でも発現される可
能性が高いものと考えられる。In addition, because Bacillus subtilis and the thermophilic bacteria, Bacillus, and Stearothermophilus that are the sources of pTHT15 have in common that they belong to the genus Bacillus, the heterologous genes already expressed in Bacillus subtilis are closely related. It is thought that there is a high possibility that it is also expressed in thermophilic bacteria.
そこで、既に枯草菌にクローン化されている遺伝子を、
本プラスミドを用いて好熱菌に移入する事によって、も
しその遺伝子産物が55℃付近での耐熱性を有するなら
ば、発酵工業における冷却コストの節減が、好熱菌によ
る発酵生産によって達成される事となる。Therefore, the genes that had already been cloned into Bacillus subtilis were
By using this plasmid to transfer into thermophilic bacteria, if the gene product has heat resistance around 55°C, reduction of cooling costs in the fermentation industry can be achieved by fermentative production by thermophilic bacteria. It happens.
また、耐熱性、耐溶媒性等の性質に優れた好熱菌の酵素
の遺伝子を、本プラスミドをベクターとして好熱菌宿主
にクローン化し、その量産を図る事によって、バイオリ
アクター等への応用が可能であり、工業プロセスへの応
用が期待される。In addition, by cloning the enzyme gene of thermophilic bacteria, which has excellent properties such as heat resistance and solvent resistance, into a thermophilic bacterial host using this plasmid as a vector and mass producing it, it will be possible to apply it to bioreactors, etc. This is possible and is expected to be applied to industrial processes.
1)THT15の入手は、本発明者らが土壌中から新た
に分離した中等度好熱菌、バチルス・ステアロサーモフ
ィルT15株をTYS培地により対数増殖後期迄増殖さ
せて得た菌体を、リゾチーム、SDS処理によって溶菌
させる事によって達せられる。1) THT15 was obtained by growing Bacillus stearothermophile strain T15, a moderate thermophilic bacterium newly isolated from soil by the present inventors, in TYS medium until late logarithmic growth. Lysozyme is achieved by lysing the bacteria by SDS treatment.
また、バチルス、ステアロサーモフィルス株は好気性の
有胞子桿菌、ダラム染色陽性であり、生育至適湿度が約
55℃で37℃では生育しない菌株であるがI)THT
15を保有する点では従来には認められない新規な微生
物である。In addition, Bacillus and Stearothermophilus strains are aerobic sporobacilli, positive for Durham staining, and the optimal humidity for growth is approximately 55°C, although they do not grow at 37°C, but I) THT
It is a novel microorganism that has not been recognized before in that it possesses 15.
本菌株はテトラサイクリンに対して耐性を示したのみな
らずクロラムフェニコール、エリスロマイシンに対して
も耐性を示し、アンピシリン、カナマイシン、ネオマイ
シン、ストレプトマイシンには感受性を示した。This strain was not only resistant to tetracycline, but also chloramphenicol and erythromycin, and sensitive to ampicillin, kanamycin, neomycin, and streptomycin.
なお、本菌株は微工研菌寄第6661号として寄託され
ている。This strain has been deposited as Microtechnical Research Institute No. 6661.
以下、実施例により本発明をより具体的に詳述する。Hereinafter, the present invention will be explained in more detail with reference to Examples.
実施例1(菌株のスクリーニング)
茨城県筑波郡谷田部町の土壌サンプル約19をTYS培
地(ディフコトリプトン2%、ディフコイースト、エキ
ストラクト19J、NaC11%)100 m lに加
え55℃で約8時間振盪培養後、テトラサイクリン(2
0μ、9/ml)を含むTYS寒天板上で生育したコロ
ニーの一つからバチルス、アテアローサフイルスTI5
株(微工研菌寄第6661号)が得られた。Example 1 (Screening of bacterial strains) Approximately 19 soil samples from Yatabe Town, Tsukuba District, Ibaraki Prefecture were added to 100 ml of TYS medium (Difco Tryptone 2%, Difco Yeast, Extract 19 J, NaC 11%) and incubated at 55°C to approx. After shaking culture for an hour, tetracycline (2
One of the colonies grown on a TYS agar plate containing 0μ, 9/ml) contained Bacillus, Atearosavirus TI5.
strain (Feikoken Bibori No. 6661) was obtained.
実施例 2
プラスミドpT)(T15のバチルス、ステアロサーモ
フィルスT15株からの分離
バチルス、ステアロサーモフィルスT15株((微工研
菌寄第6661号)の生物学的に純粋な培養基から10
0 m lのテトラサイクリン20μ9/m1を含むT
YS培地(ディフコ、バクト、′トリプトン2係、ディ
フコ、イースト、エキストラクト1係、NaC11%)
に接種し55℃で16〜18時間振盪培養する。Example 2 Plasmid pT) (Bacillus T15, isolated from Stearothermophilus strain T15, Bacillus pT) isolated from a biologically pure culture medium of Stearothermophilus strain T15 ((Feikoken Bacterial Serial No. 6661))
T containing 0 ml of tetracycline 20μ9/ml
YS medium (Difco, Bacto, Tryptone Part 2, Difco, Yeast, Extract Part 1, NaC 11%)
and cultured with shaking at 55°C for 16 to 18 hours.
この培養液を11のテトラサイクリン20μ9/m1を
含有するTYS培地に接種し、55℃で5時間培養する
。This culture solution is inoculated into TYS medium containing 20 μ9/ml of 11 tetracyclines and cultured at 55° C. for 5 hours.
菌体を遠心によって集め、T E S (20mMTi
sr−HCI 、5mMEDTA、100mMNaC1
pH7,5)で洗浄後菌体湿重量4g当り、10m1の
25%シヨ糖含有TBSに懸濁する。The bacterial cells were collected by centrifugation, and TES (20mMTi
sr-HCI, 5mM EDTA, 100mM NaCl
After washing with pH 7.5), each 4 g of wet bacterial cells was suspended in 10 ml of TBS containing 25% sucrose.
リゾチーム(10μ、9/ml)を2ml、0.25M
−EDTA(PH8,0)4mlを加え0℃で10分間
静置、続いて37℃に10分間保温する。2ml of lysozyme (10μ, 9/ml), 0.25M
- Add 4 ml of EDTA (PH8,0) and let stand at 0°C for 10 minutes, then incubate at 37°C for 10 minutes.
この細泡混合液に2mlの10%SDS、5mlの5M
−NaC1を加え4℃に15〜18時間静置する。Add 2 ml of 10% SDS, 5 ml of 5M to this fine foam mixture.
-Add NaCl and leave at 4°C for 15-18 hours.
これを2800Orpm、1時間の超遠心によって遠心
し、上清を得る。This is centrifuged by ultracentrifugation at 2800 rpm for 1 hour to obtain a supernatant.
この上清にポリエチレングリコール6000を10%(
w/v)加え、2〜3時間0℃に静置220Orpm、
2分の遠心で沈澱を得る。To this supernatant, add 10% polyethylene glycol 6000 (
w/v) and left at 0°C for 2 to 3 hours at 220 Orpm.
Obtain a precipitate by centrifuging for 2 minutes.
この沈澱を15m1のTBSに溶解し、CsCl及びエ
チジウムブロマイドを加えて密度を1.61〜1.62
に調整する。This precipitate was dissolved in 15 ml of TBS and CsCl and ethidium bromide were added to bring the density to 1.61-1.62.
Adjust to.
この試料を3800Orpmで30〜40時間、平衝密
度勾配遠心する。This sample is subjected to density gradient centrifugation at 3800 rpm for 30-40 hours.
生じたプラスミドDNAのバンドを集め、イソアミルア
ルコールでエチジウムブロマイドを除去した後、TEN
(20mMTris−HCI 、1mMEDTA、20
mMNaC1)に透析する事によって純粋なpTHTl
5が得られる。The resulting plasmid DNA bands were collected, ethidium bromide was removed with isoamyl alcohol, and then TEN
(20mM Tris-HCI, 1mM EDTA, 20mM Tris-HCI, 1mM EDTA, 20mM
Pure pTHTl was obtained by dialysis against mMNaC1).
5 is obtained.
pTHTl5の特性決定の手順
pTHTl 5の分子量は、その超らせん構造(5up
ercoiled 5tructure )のDNA
及び制限酵素によって切断された断片のアガロースゲル
電気泳動より得られた。Procedure for characterizing pTHTl5 The molecular weight of pTHTl5 is determined by its superhelical structure (5up
ercoiled 5structure) DNA
and obtained by agarose gel electrophoresis of fragments cleaved with restriction enzymes.
この際の分子量マーカーはpBR322DNA(2,6
7md)、Co1EIDNA (4,2m d )及び
ラムダDNAのHind■分解断片(14,6、5,8
4、4,05、2,67。The molecular weight marker at this time was pBR322DNA (2,6
7m d), Co1EI DNA (4,2m d) and Hind-digested fragment of lambda DNA (14,6,5,8
4, 4, 05, 2, 67.
1.04 、1.21 、0.34md )、ラムダD
NAのEcoRI分解断片(,13,7、4,74、3
,73。1.04, 1.21, 0.34md), Lambda D
EcoRI-digested fragment of NA (,13,7,4,74,3
, 73.
3.48 、3.02 、2.13md )を用いた。3.48, 3.02, 2.13md) were used.
制限酵素による切断は、プラスミドDNA溶液からエタ
ノール沈澱によってDNAを沈澱させ、適当な緩衝液に
溶解して行なった。Cleavage with restriction enzymes was carried out by precipitating DNA from a plasmid DNA solution by ethanol precipitation and dissolving it in an appropriate buffer.
制限酵素は全酒造より市販品を用いた。Restriction enzymes were commercially available from Zenshuzo.
アガロースゲル電気泳動はシーケム社のアガロースを0
.5係又は0.7%濃度で用い、水平ゲル電気泳動槽に
よってゲル長さ1crIl当り1,5vの定電圧で15
〜17時間行なった。For agarose gel electrophoresis, SeChem agarose was used at 0.
.. 5 or at a concentration of 0.7%, using a horizontal gel electrophoresis chamber at a constant voltage of 1.5 V per crIl of gel length.
It lasted ~17 hours.
pTHTl5が、そのDNA上にテトラサイクリン耐性
遺伝子を有している事は、枯草菌バチルス、ズブチルス
RM125株プロトプラストへの形質転換実験によって
確かめられた。It was confirmed that pTHTl5 has a tetracycline resistance gene on its DNA by a transformation experiment into Bacillus subtilis, Bacillus subtilis RM125 strain protoplasts.
バチルス。ズブチルRM125株のプロトプランの調製
、形質転換、プロトプラストの再生の手順はChang
& Cohenの方法(Mo Ie C,Gen 、
Gene t 。Bacillus. Chang
&Cohen's method (Mo Ie C, Gen,
Genet.
168.111−115(1979))によって行なっ
た。168.111-115 (1979)).
この方法の概略はRM125株の対数増殖菌体を等張液
中でリゾチーム処理によってプロトプラスト化し、この
プロトプラスト懸濁液にプラスミドDNA溶液を加え、
ポリエチレングリコール6000によってDNAのプロ
トプラスト内への取込みを促した後、再生培地でプロト
プラストから栄養細胞への再生を図るというものである
。The outline of this method is to convert logarithmically grown bacterial cells of strain RM125 into protoplasts by treating with lysozyme in an isotonic solution, add a plasmid DNA solution to this protoplast suspension,
After promoting the uptake of DNA into protoplasts using polyethylene glycol 6000, the protoplasts are regenerated into vegetative cells using a regeneration medium.
pTHTl 5DNA約1μ9を用いて、RM125株
のプロトプラスト懸濁液0.5m1(2X109プロト
プラスト/mりに対して形質転換を行ない、再生培地上
でテトラサイクリン耐性株の出現を検討したところ、こ
の際のプロトプラストの再生率10係(2X108AI
)に対して1×103/m1の順度でテトラサイクリン
耐性株が生じた。Approximately 1 μ9 of pTHTl 5 DNA was used to transform 0.5 ml of protoplast suspension of RM125 strain (2 x 109 protoplasts/m), and the appearance of tetracycline-resistant strains on the regeneration medium was examined. Play rate of 10 (2X108AI
), tetracycline-resistant strains occurred at an order of 1 x 103/ml.
一方、プラスミドDNA溶液を加えなかった系(コンナ
ロール)ではテトラサイクリン耐性株は2×108個以
紹のプロトプラストを徹いても生じてはこなかった。On the other hand, in the system to which no plasmid DNA solution was added (connarol), no tetracycline-resistant strains were generated even after passing through 2 x 108 or more protoplasts.
ここで得られたRM125株のテトラサイクリン耐性株
よりプラスミドDNAを、バチルス6ステアロサーモフ
イルズTI5株よりのプラスミドDNAの抽出の際と同
様(リゾチーム処理の湿度及び時間が37°G30分間
である点が異なる)の方法で抽出し検討したところ、T
)THT15と同一分子量で、制限酵素による切断パタ
ーンも全く同一なプラスミドDNAが回収された。Plasmid DNA was extracted from the tetracycline-resistant RM125 strain obtained here in the same manner as in the extraction of plasmid DNA from Bacillus 6 stearothermophilus TI5 strain (the humidity and time of lysozyme treatment was 37°G for 30 minutes). When extracted and examined using the method (different), it was found that T
) Plasmid DNA with the same molecular weight as THT15 and exactly the same cleavage pattern with restriction enzymes was recovered.
この事実は、pTHT15がテトラサイクリン耐性遺伝
子を有しており、このプラスミドがRM125株に入っ
た事によってRM125株がテトラサイクリン耐性の形
質を示すに到った事を証明するものである。This fact proves that pTHT15 has a tetracycline resistance gene, and that this plasmid was introduced into the RM125 strain, which caused the RM125 strain to exhibit the tetracycline resistance trait.
同時に、T)THT15が、好熱菌及び枯草菌で、自律
的増殖能及び形質の発現が可能なプラスミドである事、
つまり本プラスミドが両菌株でベクターとして利用し得
る事実を明らかにするものである。At the same time, T) THT15 is a plasmid capable of autonomous growth and expression of traits in thermophilic bacteria and Bacillus subtilis;
In other words, this study reveals the fact that this plasmid can be used as a vector for both strains.
テトラサイクリン耐性を有する好熱菌のプラスミドとし
ては前記の表に示したとおりであるが、pTHT15と
他のものでは前述のように明らかに異なっており、I)
THT15は従来認ちられない新規なプラスミドである
。The plasmids of thermophilic bacteria having tetracycline resistance are as shown in the table above, but as mentioned above, pTHT15 and the others are clearly different, and I)
THT15 is a novel plasmid that has not been previously recognized.
図面はpTHT15の制限酵素開裂地図を示し、図中の
CIaIはカリオファノン、ラツム由来の酵素、E c
o RIはエシェリヒア、コリ由来の酵素、HhaI
はハエモフイルス、ハエモリティカス由来の酵素、Hp
al はハエモフイルズ、パラインフルエンザ゛工由来
の酵素、Hp a IIはハエモフイルス、パラインフ
ルエンザ゛工由来の酵素、TaqIはサーマス、アクア
ティカス由来の酵素をそれぞれ示している。The figure shows a restriction enzyme cleavage map of pTHT15, and CIaI in the figure represents caryophanone, an enzyme derived from Latum, and E c
o RI is an enzyme derived from Escherichia coli, HhaI
is an enzyme derived from Haemophilus haemolyticus, Hp
al represents an enzyme derived from Haemophilus or parainfluenza, Hp a II represents an enzyme derived from Haemophilus or parainfluenza, and TaqI represents an enzyme derived from Thermus or Aquaticus.
Claims (1)
の分子量が約2.8メガダルトンであり、図に示される
制限酵素地図で特徴づけられるテトラサイクリン耐性を
備えた新規なプラスミド。1. A novel plasmid with tetracycline resistance, which internally carries a tetracycline resistance gene, has a molecular weight of approximately 2.8 megadaltons, and is characterized by the restriction enzyme map shown in the figure.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57157366A JPS5928396B2 (en) | 1982-09-09 | 1982-09-09 | Novel plasmid with tetracycline resistance |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57157366A JPS5928396B2 (en) | 1982-09-09 | 1982-09-09 | Novel plasmid with tetracycline resistance |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5946297A JPS5946297A (en) | 1984-03-15 |
| JPS5928396B2 true JPS5928396B2 (en) | 1984-07-12 |
Family
ID=15648079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57157366A Expired JPS5928396B2 (en) | 1982-09-09 | 1982-09-09 | Novel plasmid with tetracycline resistance |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5928396B2 (en) |
-
1982
- 1982-09-09 JP JP57157366A patent/JPS5928396B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5946297A (en) | 1984-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Minsavage et al. | Plasmid-mediated resistance to streptomycin in Xanthomonas campestris pv. vesicatoria. | |
| Somkuti et al. | Distribution and analysis of plasmids in Streptococcus thermophilus | |
| Mercado-Blanco et al. | Stability and transmissibility of the cryptic plasmids of Rhizobium meliloti GR4: their possible use in the construction of cloning vectors for rhizobia | |
| CA1150169A (en) | Broad host range small plasmid rings as cloning vehicles | |
| EP0077664B1 (en) | Recombinant dna and coliform bacillus having genetic material for the production of staphylokinase, and the production of staphylokinase | |
| JPS5928396B2 (en) | Novel plasmid with tetracycline resistance | |
| JPS5831988A (en) | Novel cloning vehicle | |
| US4376164A (en) | Process for preparing broad host range small plasmid rings as cloning vehicles | |
| JPS5928392B2 (en) | Novel microorganism harboring tetracycline resistance plasmid | |
| US4418194A (en) | DNA Fragments for forming plasmids | |
| JPS5923793B2 (en) | A novel plasmid with tetracycline resistance and a new microorganism carrying it | |
| JPS5953831B2 (en) | A new microorganism carrying a new plasmid | |
| JPS5923792B2 (en) | A novel plasmid with tetracycline resistance and a novel microorganism carrying it | |
| JPS5953837B2 (en) | Novel plasmid derived from highly thermophilic bacteria | |
| JPS5945358B2 (en) | Novel plasmid with neomycin and kanamycin resistance | |
| JPS5945878A (en) | Novel microogranism having neomycin- and kanamycin- resistant plasmid | |
| Lathigra et al. | Organization of the adenyl cyclase (cya) locus of Rhizobium meliloti | |
| JPS5953836B2 (en) | Novel plasmid derived from hyperthermophile | |
| JPS5978683A (en) | Novel bacterium containing novel plasmid | |
| JPS5978691A (en) | Novel plasmid derived from highly thermophilic bacterium | |
| JPS5978688A (en) | Novel plasmid derived from highly thermophilic bacterium | |
| JPS5953832B2 (en) | A new microorganism carrying a new plasmid | |
| JPH0579308B2 (en) | ||
| JPS61205484A (en) | Novel plasmid | |
| JPH0231676A (en) | Midecamycin-tolerant gene |